Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Core Insights - Fractyl Health, Inc. is focused on innovative metabolic therapeutics aimed at addressing the root causes of obesity and type 2 diabetes (T2D) [1][3] - The company will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's 85th Scientific Sessions [1][2] Company Overview - Fractyl Health is dedicated to transforming the treatment of metabolic diseases from chronic management to durable, disease-modifying therapies [3] - The company is based in Burlington, Massachusetts, and aims to tackle the increasing prevalence of obesity and T2D, which are significant contributors to morbidity and mortality in the 21st century [3] Rejuva Platform - The Rejuva platform is focused on developing next-generation adeno-associated virus (AAV)-based gene therapies specifically for obesity and T2D [4] - Currently in preclinical development, the Rejuva platform utilizes advanced delivery systems and proprietary screening methods to identify gene therapy candidates targeting the pancreas [4] - The goal of the Rejuva program is to provide novel therapies that address the underlying causes of metabolic diseases [4]